Please check your internet connection and try again.
# Ticagrelor (Brilinta)
## Overview
Ticagrelor is an oral, direct-acting, reversibly binding P2Y$_{12}$ platelet inhibitor. It is part of a dual antiplatelet therapy (DAPT) regimen.
## Primary Indications
* Reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
* Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) and at least one additional risk factor for occlusive thrombotic events.
## Adult Dosing
* **ACS:** 180 mg orally as a single loading dose, followed by 90 mg orally twice daily.
* **Post-MI with Risk Factors:** 90 mg orally twice daily.
* **Duration:** Typically used in DAPT for at least 12 months in ACS patients, or as long as the patient remains at high risk for ischemic events and low risk for bleeding. Duration for post-MI patients with risk factors should be individualized based on clinical assessment.
## Pediatric Dosing
* Ticagrelor is not approved for use in pediatric patients.
## Dose Adjustments
* No dose adjustments are necessary for patients with hepatic or renal impairment.
## Contraindications
* Known hypersensitivity to ticagrelor or any component of the formulation.
* Active pathological bleeding.
## Adverse Effects
* **Most Common:** Bleeding (anywhere, including gastrointestinal and intracranial), dyspnea, bradycardia.
* **Serious:** Life-threatening bleeding, ventricular pauses.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Strong inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor exposure, and strong inducers (e.g., rifampin, phenytoin) may decrease it.
* **CYP3A4 Substrates:** Ticagrelor can inhibit CYP3A4, increasing exposure to substrates like simvastatin and atorvastatin (consider dose limitation for statins).
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding. Use with caution.
* **Aspirin:** While often used concurrently, dose of aspirin >100 mg/day may increase ticagrelor's antiplatelet effect and bleeding risk. Maintenance doses of aspirin are generally recommended.
* **P-glycoprotein Inhibitors:** Potential for increased ticagrelor exposure.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor for dyspnea; assess clinical significance if persistent or bothersome.
* Periodic assessment of bleeding risk versus ischemic benefit is crucial for treatment duration decisions.
## Clinical Pearls
* Ticagrelor is a P2Y$_{12}$ inhibitor that provides rapid and potent platelet inhibition.
* It is dosed twice daily, which is distinct from other oral P2Y$_{12}$ inhibitors.
* Dyspnea is a common side effect and typically resolves with continued therapy. If severe or persistent, consider alternative antiplatelet therapy.
* Discontinuation of ticagrelor prematurely increases the risk of stent thrombosis and other thrombotic events.
* If a dose is missed, the patient should take the next dose at the regularly scheduled time and not double the dose.
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and clinical guidelines for ticagrelor.
